Human Ab-Producing Mice

Human-Antibody Producing Rodents

Multiple innovative platforms are currently available for antibody discovery using genetically modified mice that express fully-human heavy and light chain variable regions.  These animals can generate diverse repertoires of in vivo affinity-matured antibodies with intrinsic drug-like properties necessary for successful development, including high potency, specificity, solubility, and manufacturability.  A key advantage is that in having full-human variable regions, the antibodies have a low risk of immunogenicity, thus mitigating efficacy-killing anti-drug responses when reformatted as therapeutics.






Download a free eBook: Introduction to Hybridoma Technologies for Antibody Discovery

To learn more visit  hybridoma.com

PentaMice™: A Unique Approach to Achieve Maximum Plasma Titers for Antibody Discovery webinar recording available NOW!

Discovery of Potent, Functional Anti-BTLA, and Anti-TIGIT Monoclonal Antibodies using Hybridoma and Phage Display Platform webinar recording available NOW!



References
Lowitz J, Lin G, Somera J, Santibanez-Vargas L, Vo C, Rodriguez E, Nguyen B, Trang M, Nichols J, Kenney J. Optimization of Therapeutic Discovery Strategies for Human Antibody Transgenic Animal Platforms. Poster presented at PEGS; 2019 Apr. 8-12; Boston, MA.Maximizing the AlivaMab Mouse Advantage. Retrieved from https://alivamab.com/alivamab-mouse.